Skip to main
EOLS
EOLS logo

Evolus (EOLS) Stock Forecast & Price Target

Evolus (EOLS) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 31%
Hold 8%
Sell 0%
Strong Sell 8%

Bulls say

Evolus Inc reported a significant 29.4% year-over-year increase in total net revenue, reaching $78.9 million in the fourth quarter of 2023, primarily driven by a surge in Jeuveau sales alongside the acquisition of approximately 830 new accounts. The company’s adjusted gross margin remained strong at 67.5%, indicating effective cost management and stable profitability in the aesthetics market. Additionally, the anticipated launch of the Evolysse fillers is expected to enhance revenue contributions significantly, projected at 8-10% of total revenue for fiscal year 2025, which bolsters the company’s growth outlook amidst a favorable market trend emphasizing aesthetic treatments among younger consumers.

Bears say

Evolus Inc reported a GAAP net loss of $6.8 million for the fourth quarter of 2023, translating to a loss per share of $0.11, which exceeded the company's own estimate but fell short of the market consensus. The company faces significant operational challenges, including reliance on third-party suppliers for manufacturing Jeuveau, posing risks related to supply chain disruptions and competitive pressures from larger firms. Additionally, increasing operating expenses associated with the marketing of Jeuveau and the development of extra-strength formulations heighten financing risks that could impact future financial performance.

Evolus (EOLS) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 31% recommend Buy, 8% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolus (EOLS) Forecast

Analysts have given Evolus (EOLS) a Buy based on their latest research and market trends.

According to 13 analysts, Evolus (EOLS) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolus (EOLS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.